{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:54:57Z","timestamp":1791482097333,"version":"4.3.4"},"reference-count":62,"publisher":"Mark Allen Group","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Nurs"],"published-print":{"date-parts":[[2026,10,8]]},"abstract":"<jats:p>Research question: What is the latest evidence on the efficacy and safety of combining medications to treat overactive bladder? The problem: Overactive bladder symptoms negatively impact quality of life and, with an ageing population, overactive bladder prevalence is expected to rise. Current treatments do not adequately address all patients\u2019 needs, with concerns about dementia risk from antimuscarinics, and not all patients wish to proceed to invasive procedures. This highlights the need for alternative pharmacological strategies. Literature review: The literature emphasises the detrimental impact of overactive bladder on patients\u2019 daily lives and highlights safety concerns, particularly cognitive risks linked to traditional antimuscarinics. Methodology: Nine randomised controlled trials were critically appraised for methodological quality and risk of bias, with findings synthesised narratively due to study heterogeneity. Results: Explored combinations include beta-3 adrenoreceptor agonists (vibegron or mirabegron) with antimuscarinics, beta-3 adrenoreceptor agonists with phosphodiesterase 5 inhibitors, and antimuscarinics with cholinergic agonists. These combinations demonstrated improved efficacy and tolerability in treating overactive bladder while minimising side effects. Most studies report symptom improvement without increased cardiovascular risk. Conclusions: Combination therapies demonstrate superior efficacy compared to monotherapy without increasing anticholinergic burden, offering promising treatment alternatives. These findings support the expansion of new agents (vibegron) and novel pharmacological combinations in nursing practice to improve patient outcomes while considering safety profiles. However, methodological limitations such as sample bias and potential funding bias should be noted.<\/jats:p>","DOI":"10.12968\/bjon.2026.0126","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:10:26Z","timestamp":1791479426000},"source":"Crossref","is-referenced-by-count":0,"title":["The combined medication approach for treating overactive bladder: assessing safety and efficacy"],"prefix":"10.12968","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3915-198X","authenticated-orcid":false,"given":"Lucy","family":"Henderson","sequence":"first","affiliation":[{"name":"Urology Nurse Consultant, Health and Care Jersey, Government of Jersey, The Enid Quenault Health &amp; Wellbeing Centre, St Brelade, Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Hughes","sequence":"additional","affiliation":[{"name":"Urology Consultant, Health and Care Jersey, Government of Jersey, The Enid Quenault Health &amp; Wellbeing Centre, St Brelade, Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5130","reference":[{"key":"e_1_3_2_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuro.2018.06.002"},{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1817377"},{"key":"e_1_3_2_3_1","unstructured":"British Association of Urological Surgeons. Incontinence of urine. 2024. https:\/\/www.baus.org.uk\/patients\/conditions\/5\/incontinence_of_urine (accessed 21 September 2026)"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-009-0033-y"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.229"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2016.11.008"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12152"},{"key":"e_1_3_2_8_1","unstructured":"Cornu JN Elterman D Hashim H et al. 2024. EAU guidelines on nonneurogenic male lower urinary tract symptoms. European Association of Urology. 2026. https:\/\/uroweb.org\/guidelines\/management-of-non-neurogenic-male-luts (accessed 21 September 2026)"},{"key":"e_1_3_2_9_1","unstructured":"Department of Health. Research governance framework for health and social care. 2005. Withdrawn in 2017. https:\/\/www.gov.uk\/government\/publications\/research-governance-framework-for-health-and-social-care-second-edition (accessed 21 September 2026)"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12409"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.24536"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.030"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-016-2945-4"},{"key":"e_1_3_2_14_1","first-page":"2","article-title":"Gender differences in overactive bladder","volume":"23","author":"Eapen RS","year":"2016","unstructured":"Eapen RS, Radomski SB. Gender differences in overactive bladder. Can J Urol. 2016 Feb; 23 Suppl 1:2\u20139.","journal-title":"Can J Urol"},{"key":"e_1_3_2_15_1","unstructured":"Economic and Social Research Council. Framework for research ethics 2018. https:\/\/www.ukri.org\/councils\/esrc\/guidance-for-applicants\/research-ethics-guidance\/framework-for-research-ethics\/ (accessed 21 September 2026)"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.7663"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.07.010"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-020-1474-7"},{"key":"e_1_3_2_19_1","unstructured":"Harding CK Lapitan MC Arlandis S et al. EAU guidelines on management of nonneurogenic female lower urinary tract symptoms. European Association of Urology. 2026. https:\/\/uroweb.org\/guidelines\/non-neurogenic-female-luts (accessed 21 September 2026)"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-018-0892-0"},{"key":"e_1_3_2_21_1","volume-title":"The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Version 5.1.0","author":"Higgins JPT","year":"2011","unstructured":"Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S (eds); The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. John Wiley and Sons; 2011. ISBN: 978-1119964797. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v5.1.0 (accessed 21 September 2026)"},{"key":"e_1_3_2_22_1","volume-title":"Cochrane handbook for systematic reviews of interventions. Version 5.1.0","author":"Higgins JPT","year":"2011","unstructured":"Higgins JPT, Green S. (eds): The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. John Wiley and Sons; 2011. ISBN: 978-1119964797 https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v5.1.0 (accessed 21 September 2026)"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180986"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2021.01.021"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.24158"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12286"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","unstructured":"Kennelly M Wielage R Shortino D Thomas E Mudd PN Jr. Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis. Drugs Context. 2022; 11. 10.7573\/dic.2022-4-2","DOI":"10.7573\/dic.2022-4-2"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000281"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urols.2014.12.007"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.4103\/tcmj.tcmj_209_21"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-6646(10)60133-7"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20928"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/13697137.2018.1543263"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.10.006"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23919"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000596"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.12.031"},{"key":"e_1_3_2_39_1","unstructured":"National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women NICE guideline NG123. 2019 https:\/\/www.nice.org.uk\/guidance\/ng123 (accessed 21 September 2026)"},{"key":"e_1_3_2_40_1","unstructured":"National Institute for Health and Care Excellence Urinary incontinence in women. NICE Quality standard QS77. 2021 (updated from 2015). https:\/\/www.nice.org.uk\/guidance\/qs77 (accessed 21 September 2026)"},{"key":"e_1_3_2_41_1","unstructured":"National Institute for Health and Care Excellence. Lower urinary tract symptoms in men Clinical guideline CG97. 2024a (updated from 2015 and 2010; reviewed in 2024). https:\/\/www.nice.org.uk\/guidance\/cg97 (accessed 21 September 2026)"},{"key":"e_1_3_2_42_1","unstructured":"National Institute for Health and Care Excellence. 2024b. Vibegron for treating symptoms of overactive bladder syndrome. Technology appraisal guidance: TA999. 2024. https:\/\/www.nice.org.uk\/guidance\/ta999 (accessed 21 September 2026)"},{"key":"e_1_3_2_43_1","first-page":"181","article-title":"The Nuremberg Code. In: Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10. Nuremberg, October 1946\u2013April 1949","volume":"2","author":"Nuremberg Military Tribunals","year":"1949","unstructured":"Nuremberg Military Tribunals. The Nuremberg Code. In: Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10. Nuremberg, October 1946\u2013April 1949. US Government Printing Office. 1949;2:181\u2013182","journal-title":"US Government Printing Office"},{"key":"e_1_3_2_44_1","unstructured":"Office for National Statistics. National population projections: 2022-based. 2025. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationprojections\/bulletins\/nationalpopulationprojections\/2022based (accessed 21 September 2026)"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11884-019-00562-3"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12194"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2018.04.005"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.7326\/acpjc-1995-123-3-a12"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1315"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijosm.2016.04.005"},{"key":"e_1_3_2_51_1","unstructured":"Ryan R; Cochrane Consumers and Communication Review Group. Cochrane Consumers and Communication: data synthesis and analysis. 2013. https:\/\/cccrg.cochrane.org\/sites\/cccrg.cochrane.org\/files\/uploads\/AnalysisRestyled.pdf (accessed 29 September 2026)"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.12451"},{"key":"e_1_3_2_53_1","unstructured":"Saylor BP. Beta 3 agonists: a \u2018much-needed alternative\u2019 for patients with OAB. Urology Times. 27 April 2022. https:\/\/www.urologytimes.com\/view\/beta-3-agonists-a-much-needed-alternative-for-patients-with-oab (accessed 21 September 2026)"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-8-18"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.029"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/jme.2010.039941"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11023.x"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098616659412"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.28105"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13868"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.24285"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0317550"}],"container-title":["British Journal of Nursing"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.magonlinelibrary.com\/doi\/pdf\/10.12968\/bjon.2026.0126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:24:11Z","timestamp":1791480251000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.magonlinelibrary.com\/doi\/10.12968\/bjon.2026.0126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":62,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,10,8]]}},"alternative-id":["10.12968\/bjon.2026.0126"],"URL":"https:\/\/doi.org\/10.12968\/bjon.2026.0126","relation":{},"ISSN":["0966-0461","2052-2819"],"issn-type":[{"value":"0966-0461","type":"print"},{"value":"2052-2819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]}}}